Don’t miss the workshop & 2 presentations by our colleagues Marc-André Kasper & Olivier Marcq, discussing linker selection & novel #conjugation technologies at the upcoming #ADC Linker & Conjugation Summit starting tomorrow in #Boston. 🛈 Agenda details

Join the Tubulis team in Boston for #BIO2023. With the recent momentum in the #ADC space, we are looking forward to connecting with industry partners & the investor community to share the potential applications of our candidates for the future of #cancer treatment.

Our CSO Jonas Helma-Smets will present a virtual poster on our novel #Alco5 platform highlighting its powerful potential to access a new spectrum of payloads for #ADC development @PEGSboston this week. Connect with him virtually to learn more! #solidtumors

Attending the upcoming #BioEquity 2023? Meet our CEO, Dominik Schumacher on-site to discuss the latest #ADC developments and how our pipeline candidates aim to deliver the true potential of antibody-drug conjugates to #cancer patients.

We are joining forces with @bmsnews in a strategic #licensing agreement to develop differentiated next-generation antibody-drug conjugates (#ADCs) for the treatment of #cancer! Read the full PR here:

Our CSO, Jonas Helma-Smets, & CDO, Björn Hock, are looking forward to the upcoming @World_ADC in #London! Interested to discuss our pipeline of highly stable & efficient #cancer #ADCs fueled by our novel #conjugation platforms? Reach out via contact@tubulis.com for a chat on-site

We made it on the cover of the latest issue of the @RoySocChem’s flagship journal Chemical Science! Read our joint paper with @PhosphorusFive highlighting our novel P5-technology to create #ADCs with improved efficacy & PK here: Cover by @BarthvanRossum

Attending the Next-Gen Conjugates Summit? Don’t miss the talk by our Director of Chemistry & Early Discovery, Marc-André Kasper, about our P5 & Alco5 platforms to create stable & efficient #ADCs & broaden the scope of drugs available for conjugation:

We are excited to announce the appointment of Björn Hock, PhD, as Chief Development Officer! He has been advising us since 2020 & will support the rapid advancement of our #ADC candidates toward the clinic & expansion of our pipeline. Read the full PR here

Listen to our Head of Research Chemistry, Marc-André Kasper, talking about improvements in #ADC payload delivery targeting topoisomerase-I at the #FestivalOfBiologics on Nov 2 at 2:20pm CET. Find the agenda here

Interested in meeting the Tubulis Team at #BIOEurope 2022 in Leipzig to discuss the future of #ADCs? Reach out to us via BIO-Europe’s #partnering portal:

Congratulations to this year’s #Nobelprize winners in #Chemistry, particularly @CarolynBertozzi, whose bioorthogonal reactions are key for the improvement of targeted #cancer pharmaceuticals, including modern #ADCs. This is well deserved!

#DYK there are 500.000 newly diagnosed cancer patients in Germany per year? #WorldCanceResearchDay reminds us to never stop looking for a cure! At Tubulis we create advanced #ADCs to deliver better outcomes for patients. Find out how @

Don’t miss our CMO, Günter Fingerle-Rowson @EORTC’s CLTG meeting where he will present new data on our #lymphoma-targeting #ADC candidate TUB-010, based on our Tub-tag conjugation technology. For more information:

Check out our joint publication with @LMU_Uniklinikum, DKTK & @LeibnizFMP in @BloodJournal on 20D9-ADC, an #ADC created with our P5 conjugation technology targeting FTL3 in #AML, showing significant & durable tumor reduction in mouse models. Click here:

Don’t miss our CEO Dominik Schumacher giving a talk at the @World_ADC congress in San Diego tomorrow about our unique conjugation technologies to enable safe payload delivery & make the right match when it comes to #ADC design.

Interested in the future of #ADCs? Talk to our team at the upcoming @World_ADC congress in San Diego about our partnering & collaboration opportunities. Reach out to us via info@tubulis.com for a chat on-site.

Check out the latest issue of @PharmaReview, where our CEO Dominik Schumacher & CSO Jonas Helma-Smets discuss advancements in #ADC development & how Tubulis’ unique conjugation platform approach aims to address current shortcomings in the field:

Meet our CEO Dominik Schumacher & CSO Jonas Helma-Smets at the @World_ADC congress in San Diego, where they will give two presentations on Tubulis’ differentiated #ADC platform approaches. To connect with us on site, reach out via info@tubulis.com.

RT @BioconjChem: Next generation bioconjugates against influenza virus infection: The Hackenberger group @PhosphorusFive @LeibnizFMP and He…